Axiom-4 to Test First FDA-Approved Cancer Drug in Space, Pioneering Microgravity-Driven Oncology Research
In a landmark development for pharmaceutical research, the upcoming Axiom-4 (Ax-4) mission is set to test Rebecsinib, the first cancer […]
Tags: ADAR1 inhibitor, Aspera Biomedicines, Axiom-4, B2B healthcare innovation, biopharma space mission, cancer stem cells, FDA-approved space research, IND status cancer drug, microgravity drug testing, oncology R&D, preclinical testing in space, Rebecsinib, space pharma innovation, space-based cancer research, tumour organoids, UC San Diego Sanford Stem Cell Institute
